Inactive Instrument

Press Releases OYSR POIN

Equities

OYST

US69242L1061

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

OYSTER POINT PHARMA, INC. : Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	23-01-03	AQ
OYSTER POINT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Oyster Point Pharma, Inc. - OYST	22-12-07	BU
Oyster Point Pharma Inc., Reports Inducement Grants Under Nasdaq Listing Rule 5635	22-12-05	AQ
Oyster Point Pharma, Inc., Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	22-12-02	GL
Oyster Point Pharma, Inc., Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	22-12-02	AQ
OYSTER POINT PHARMA, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	22-11-10	AQ
Oyster Point Pharma Reports Third Quarter 2022 Financial Results and Recent Business Highlights	22-11-10	GL
Oyster Point Pharma Reports Third Quarter 2022 Financial Results and Recent Business Highlights	22-11-10	AQ
OYSTER POINT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Oyster Point Pharma, Inc. - OYST	22-11-08	BU
OYSTER POINT PHARMA, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)	22-11-08	AQ
Oyster Point Pharma a Leading Ophthalmology-Focused Biopharmaceutical Company, to be Acquired by Viatris	22-11-08	AQ
OYST Alert: Monsey Firm of Wohl & Fruchter LLP Investigating Sale of Oyster Point Pharma, Inc.	22-11-07	AQ
OYSTER POINT PHARMA, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	22-11-07	AQ
Oyster Point Pharma, a Leading Ophthalmology-Focused Biopharmaceutical Company, to be Acquired by Viatris	22-11-07	GL
Oyster Point Pharma, a Leading Ophthalmology-Focused Biopharmaceutical Company, to be Acquired by Viatris	22-11-07	AQ
Oyster Point Pharma Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635	22-11-03	AQ
Oyster Point Pharma To Report Third Quarter 2022 Financial Results On November 10, 2022	22-11-02	GL
Oyster Point Pharma To Report Third Quarter 2022 Financial Results On November 10, 2022	22-11-02	GL
Oyster Point Pharma, Inc., Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	22-11-02	GL
Oyster Point Pharma, Inc., Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	22-11-02	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases OYSR POIN

Equities

OYST

US69242L1061

Press Releases

Filters